SG Americas Securities LLC Acquires New Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)

SG Americas Securities LLC acquired a new stake in Perspective Therapeutics, Inc. (NYSE:CATX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 18,461 shares of the company’s stock, valued at approximately $246,000.

Several other hedge funds have also recently bought and sold shares of CATX. Vanguard Group Inc. raised its position in shares of Perspective Therapeutics by 34.6% during the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after buying an additional 4,566,356 shares in the last quarter. Janus Henderson Group PLC purchased a new position in shares of Perspective Therapeutics in the first quarter worth approximately $15,511,000. Affinity Asset Advisors LLC acquired a new stake in shares of Perspective Therapeutics during the first quarter worth approximately $6,069,000. Ally Bridge Group NY LLC acquired a new stake in shares of Perspective Therapeutics during the second quarter worth approximately $3,951,000. Finally, WealthPLAN Partners LLC acquired a new stake in shares of Perspective Therapeutics during the second quarter worth approximately $1,695,000. 54.66% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CATX has been the subject of a number of analyst reports. Wedbush initiated coverage on shares of Perspective Therapeutics in a research note on Tuesday, October 1st. They issued an “outperform” rating and a $25.00 target price for the company. Truist Financial initiated coverage on shares of Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price objective for the company. Oppenheimer restated an “outperform” rating and issued a $22.00 price objective on shares of Perspective Therapeutics in a research note on Friday, October 11th. Royal Bank of Canada reduced their price objective on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating for the company in a research note on Friday, August 16th. Finally, Bank of America initiated coverage on shares of Perspective Therapeutics in a research note on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Perspective Therapeutics presently has an average rating of “Buy” and an average price target of $21.43.

Perspective Therapeutics Stock Up 0.8 %

NYSE:CATX opened at $12.75 on Tuesday. Perspective Therapeutics, Inc. has a one year low of $2.20 and a one year high of $19.05. The firm’s fifty day moving average is $13.88.

Perspective Therapeutics (NYSE:CATX) last released its earnings results on Monday, August 12th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. As a group, analysts forecast that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current fiscal year.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.